Cardiac Catheterization Laboratory of the Cardiovascular Institute, Mount Sinai Hospital, New York, New York 10029-6754, USA.
Catheter Cardiovasc Interv. 2009 Nov 1;74(5):700-7. doi: 10.1002/ccd.22112.
The objective of this study is to analyze the clinical outcomes and treatment strategies of coronary wire perforations (WPs) in the era of heparin use compared to the era of bivalirudin use.
Percutaneous coronary intervention (PCI) advances have led to progressive decrease in complications. Therefore, complex coronary lesions such as chronic total occlusions and calcified lesions are being attempted with stiff/hydrophilic wires with resultant higher incidence of coronary WP.
A single-center retrospective data analysis of coronary perforation (CP) for the last 4 years with review of coronary angiograms was done and WPs were identified. A simple classification scheme based on angiographic appearance of CP was made: Type I ("myocardial stain," with no frank dye extravasation) and type II ("myocardial fan," with dye extravasation to pericardial cavity or cardiac chambers).
Overall incidence of CP was 0.49% (82/16,859). Of these 50 (61%) were caused by WP; 30 occurred with heparin use (Group A) and 20 with bivalirudin use (Group B). WPs always occurred in type B2/C lesions (100%) and commonly with use of hydrophilic guidewires (70%). Major adverse cardiac events and cardiac tamponade were frequent in group A (50%) and none in group B (0%); P < 0.01. All WP in group B responded to stopping anticoagulation and prolonged balloon inflation, while group A type II perforations frequently required additional interventions (pericardiocentesis, coil embolization).
Cardiac tamponade and major adverse cardiac events from WPs were less frequent with bivalirudin use compared to heparin use. This beneficial effect of bivalirudin may be explained on the basis of its short half-life and reversible thrombin inhibition property. Therefore, bivalirudin may offer a safer alternative for anticoagulation in complex PCI.
本研究旨在分析肝素时代与比伐卢定时代经皮冠状动脉介入治疗(PCI)中冠状动脉穿孔(WP)的临床结果和治疗策略。
随着 PCI 技术的进步,并发症发生率逐渐降低。因此,目前采用硬头亲水导丝处理复杂的冠状动脉病变,如慢性完全闭塞和钙化病变,导致 WP 的发生率更高。
对过去 4 年中因 CP 进行的单中心回顾性数据分析,并对冠状动脉造影进行了回顾,确定了 WP。根据 CP 的血管造影表现制定了一种简单的分类方案:I 型(“心肌染色”,无明显染料外渗)和 II 型(“心肌扇形”,有染料外渗至心包腔或心脏腔室)。
CP 的总发生率为 0.49%(82/16859)。其中 50 例(61%)由 WP 引起;肝素组 30 例(组 A),比伐卢定组 20 例(组 B)。WP 总是发生在 B2/C 型病变(100%),且常使用亲水导丝(70%)。组 A 中主要心脏不良事件和心脏压塞发生率高(50%),组 B 中无心脏压塞(0%);P<0.01。组 B 的所有 WP 经停止抗凝和延长球囊扩张后均可缓解,而组 A 的 II 型穿孔常需要额外的介入治疗(心包穿刺、线圈栓塞)。
与肝素相比,比伐卢定的 WP 导致心脏压塞和主要心脏不良事件的发生率较低。比伐卢定的这种有益效果可能基于其半衰期短和可逆转的凝血酶抑制特性。因此,比伐卢定可能为复杂 PCI 中的抗凝提供更安全的选择。